MedTrace Logo

A Clinical Study to Evaluate the Safety and Pharmacokinetics of CKD-344

NCT04673695 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2020-12-17

No results posted yet for this study

Summary

A Clinical Trial to evaluate the Pharmacokinetics and safety of CKD-344

Conditions

  • Anticoagulant

Interventions

DRUG

Lixiana(D006)

NOAC(Factor Xa inhibitor)

DRUG

CKD-344

NOAC(Factor Xa inhibitor)

Sponsors & Collaborators

  • Chong Kun Dang Pharmaceutical

    lead INDUSTRY

Principal Investigators

  • Yook-Hwan Noh · H Plus Yangji Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-11-13
Primary Completion
2020-12-26
Completion
2021-01-02

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04673695 on ClinicalTrials.gov